Repligen | RGEN - Assets


Repligen reported $2.93B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agilent USD 13.07B 252M Mar/2026
Align Technology USD 6.31B 80.48M Mar/2026
Bio Techne USD 2.55B 27.9M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Bruker USD 6.13B 110.7M Mar/2026
Charles River Laboratories USD 7.73B 594.89M Mar/2026
Danaher USD 83.54B 80M Mar/2026
Dentsply International USD 5.23B 200M Mar/2026
General Electric Aerospace USD 127.67B 773M Jun/2026
Henry Schein USD 11.3B 89M Mar/2026
Illumina USD 6.56B 85M Mar/2026
IQVIA Holdings USD 29.68B 269M Mar/2026
Mettler Toledo International USD 3.67B 43.73M Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
OraSure Technologies USD 379.17M 24M Mar/2026
Pacific Biosciences Of California USD 782.36M 1.72M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Repligen USD 2.93B 18.93M Mar/2026
Revvity USD 12B 171.82M Mar/2026
Standard Biotools USD 639.11M 71.36M Mar/2026
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Waters USD 24.53B 19.45B Mar/2026
West Pharmaceutical Services USD 4.11B 160.2M Mar/2026